Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoAg-VAX
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
NeoAg-VAX is a personalized cancer vaccine designed to stimulate the immune system to recognize and attack tumor-specific neoantigens in patients with colorectal cancer, particularly those with microsatellite stable (MSS) metastatic disease. The vaccine is tailored for each patient by identifying unique neoantigens present in their tumor cells, which are then formulated into a vaccine to induce robust antigen-specific T cell responses. Clinical trials have demonstrated that NeoAg-VAX has a favorable safety profile, induces strong immunogenicity, and leads to dynamic changes in the tumor microenvironment that may help overcome immune evasion. It is being evaluated both as monotherapy and in combination with pembrolizumab (Keytruda), an anti-PD-1 checkpoint inhibitor[1][4][8].
- Brand names
- NeoAg-VAX
- Other names
- NeoAg-VAX
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on NeoAg-VAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoAg-VAX.